Latest in Heart & Metabolic Prevention

finance.yahoo.com
256 words

Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026

A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe's gene editing program designed to lower lipoprotein(a) CEO to participate in the inaugural AHA Innovation Forum's sessions on entrepreneurship and AI in cardiovascular innovation Scribe will…

Heart & Metabolic Prevention

BP, lipids, A1c, ASCVD risk, and lifestyle/med therapy to lower risk.

  • 4 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.